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Abstract
Background: Parkinson’s disease, schizophrenia, Huntington’s chorea and drug addiction are manifestations of
malfunctioning neurons within the striatum region at the base of the human forebrain. A key component of these
neurons is the protein DARPP-32, which receives and processes various types of dopamine and glutamate inputs
and translates them into specific biochemical, cellular, physiological, and behavioral responses. DARPP-32’s unique
capacity of faithfully converting distinct neurotransmitter signals into appropriate responses is achieved through a
complex phosphorylation-dephosphorylation system that evades intuition and predictability.
Results: To gain deeper insights into the functioning of the DARPP-32 signal transduction system, we developed a
dynamic model that is robust and consistent with available clinical, pharmacological, and biological observations.
Upon validation, the model was first used to explore how different input signal scenarios are processed by DARPP-
32 and translated into distinct static and dynamic responses. Secondly, a comprehensive perturbation analysis
identified the specific role of each component on the system’s signal transduction ability.
Conclusions: Our study investigated the effects of various patterns of neurotransmission on signal integration and
interpretation by DARPP-32 and showed that the DARPP-32 system has the capability of discerning surprisingly
many neurotransmission scenarios. We also screened out potential mechanisms underlying this capability of the
DARPP-32 system. This type of insight deepens our understanding of neuronal signal transduction in normal
medium spiny neurons, sheds light on neurological disorders associated with the striatum, and might aid the
search for intervention targets in neurological diseases and drug addiction.
Background
The basal ganglia form a functional complex of neurons
that are located at the base of the human forebrain.
Malfunctioning of this complex has been associated
with Parkinson’s disease, schizophrenia, Huntington’s
chorea, and drug addiction [1]. The basal ganglia system
receives most of its input through the striatum, which
consists primarily of medium spiny neurons. These neu-
rons are equipped with a protein, called DARPP-32
(dopamine- and cAMP-regulated phosphoprotein with
32 kDa molecular weight), that is the key mediator of
signal processing [2]. In response to dopamine signals,
DARPP-32 mediates a variety of biochemical, cellular,
and physiological effects [3,4], including changes in the
ion channel state of membranes, altered transcription
factor activity, up- or down-regulation of gene
expression, and reward [5,6]. Furthermore, DARPP-32
has important functions in behavior, such as changes in
motor activity. In addition to dopamine signals, DARPP-
32 processes excitatory glutamatergic signals from the
cortex, which are similarly crucial inputs to the striatum
[7,8]. Thus, DARPP-32 serves as a centralized location
for receiving, integrating and processing signals from
several neurotransmitters and constitutes a key element
in the important cortico-striato-pallido-thalamo-cortical
loop.
Experimental evidence has shown that DARPP-32
functions by translating the incoming neuronal signals
into distinct activity profiles of kinases and phospha-
tases. This translation process is based on phosphory-
lation and dephosphorylation at multiple sites of
DARPP-32 and accomplished through a complicated
signal transduction network that uses a second mes-
senger system and a biochemical pathway activated by
calcium (Figures 1 and 2). Specifically, when dopamine
* Correspondence: eberhard.voit@bme.gatech.edu
1Department of Biomedical Engineering, Georgia Institute of Technology and
Emory University Medical School, Atlanta, GA 30332, USA
Qi et al. BMC Systems Biology 2010, 4:26
http://www.biomedcentral.com/1752-0509/4/26
© 2010 Qi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.binds to its postsynaptic receptor of D1 subtype, a sec-
ondary messenger system is trigged that leads to the
production of cyclic AMP (cAMP). This messenger
molecule in turn activates protein kinase A (PKA).
Both cAMP and PKA are critically regulated by phos-
phodiesterase (PDE), which has multiple isoforms such
as PDE1 and PDE4 [9]. PKA then phosphorylates
DARPP-32 at a specific threonine residue (Thr34) and
thereby converts it into a potent inhibitor of protein
phosphatase-1 (PP1) [2,10]. In contrast to dopamine,
glutamate binds to its own ionotropic receptors (e.g.,
AMPA and NMDA), which causes Ca
2+ cations to flow
into the cell. This induced Ca
2+ influx reduces the
inhibition of PP1 by activating protein phosphatase 2B
(PP2B). PP2B dephosphorylates DARPP-32 at the
threonine site and enhances the inhibition of PKA by
increasing phosphorylation of DARPP-32 at another
threonine residue, which is phosphorylated by cyclin-
dependent kinase 5 (CDK5) [11-13].
The brief description of event chains indicates that the
DARPP-32 signal transduction system balances the effects
of competing triggers, which themselves are dynamic and
depend on their recent histories. As a consequence, the
integration and interpretation of neuronal signals by
DARPP-32 can vary in response to different trains of input
signals. In other words, different signal patterns, such as a
single signal vs.c o e x i s t e n ts i g n a l s ,ao n e - t i m ep u l s evs.
repetitive pulses, or signals for short-term vs.l o n g - t e r m
plasticity, can have distinct effects on rewards, learning,
memory, locomotion and/or synaptic plasticity.
The multitude of graded effects and interactions of the
complex DARPP-32 system easily evades intuition and
Figure 1 Signal integration and interpretation by the DARPP-32 system in dendrites of medium spiny neurons in the striatum.T h e
membrane of spiny neurons (solid curved line) contains receptors for the neurotransmitters dopamine and glutamate, which had been released
by other neurons into the synaptic cleft. Diamonds show molecular binding, while arrows with plus signs designate activation or enzymatic
reactions and dash-dotted lines with bars indicate inhibition. Shaded boxes in green color represent phosphorylated forms of DARPP-32, with
labels indicating the specific phosphorylated site, and arrows showing possible transitions between the different phosphorylation states. Open
block arrows indicate possible multiple-site phosphorylation. Please refer to the Figure 2 for a detailed map of all possible transitions between
different phosphorylation forms. Abbreviations are: dopamine receptor of D1 subtype (D1), dopamine receptor of D2 subtype (D2), G protein and
subunits (Gabg,G a), adenylate cyclase (AC5), cyclic AMP (cAMP), phosphodiesterases (PDE1, PDE4), protein kinase A (PKA, PKAc), alpha-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), N-methyl-D-aspartate (NMDA), protein phosphatase 2B (PP2Bi, PP2B), protein phosphatase-1
(PP1), protein phosphatase 2A (PP2A), cyclin-dependent kinase 5 (CDK5), casein kinase 2 (CK2), casein kinase 1 (CK1), protein phosphatase 2C
(PP2C), dopamine- and cAMP-regulated phosphoprotein with 32 kDa molecular weight (DARPP-32). Phosphorylation of DARPP-32 is indicated by
the corresponding amino acid and location, such as DARPP-32Thr
34. See Figure 2 for multiple-site phosphorylation.
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methods of systems biology. Such an analysis could
yield answers to questions regarding the specifics of the
operation and design of the signal transduction system.
For instance, one might ask which mechanisms are
dominant in a given signaling situation and within a
specific context. Do these mechanisms function syner-
gistically or antagonistica l l y ?T ow h a td e g r e ed ot h e y
contribute to different modes of signal integration that
are required by relevant brain functions or implicated in
neurological diseases?
The goal of this work is to investigate such questions
systematically and quantitatively with methods of com-
putational systems biology. At the core of our approach
is a dynamic model that is capable of accounting for the
many components and processes associated with the
DARPP-32 system in a numerical fashion. The details of
this model are described in the Methods Section, and
the model itself is presented explicitly and completely in
Additional file 1. Upon formulating, testing, and validat-
ing the model, we simulated various patterns of neuro-
transmission and studied their effects on signal
integration and interpretation by DARPP-32. The simu-
lations and analyses addressed both the steady-state and
the dynamics of the system. Moreover, systematic per-
turbations with the validated model revealed which
mechanisms are dominant in specific signal input situa-
tions. This type of insight deepens our understanding of
neuronal signal transduction in normal medium spiny
neurons, could possibly shed light on mechanisms of
neurological disorders associated with the striatum, and
might aid the search for intervention targets in neurolo-
gical diseases.
Results
Validation of the model
The model, as detailed in the Methods Section, serves as
an exploratory platform for scenario simulations and
their evaluations. However, before the model can be
used in this capacity, it must be tested and validated
against available experimental and clinical data on the
biochemistry, pharmacology, and electrophysiology of
the system. The available experimental observations
cover both static and dynamic behaviors of the DARPP-
32 system. Most of them were carried out on rats.
Under normal, unstimulated base conditions, the
degree of DARPP-32 phosphorylation at Thr34 and
Thr75 was experimentally determined as 0.5-1.0% and
26%, respectively [14-16]. Our model shows phosphory-
lation rates of ~0.7% and ~28.6% of total DARPP-32
molecules, respectively. The model also suggests that
phosphorylation at Ser102 and Ser137, as well as
Figure 2 Phosphorylation states of DARPP-32. Differently shaded boxes show singly, doubly and triply phosphorylated states of DARPP-32,
and labels indicate phosphorylation positions. Arrows indicate transitions between different phosphorylation forms through enzymatic reactions.
Dash-dotted lines with bars represent inhibition. Abbreviations are: protein phosphatase-1 (PP1), protein kinase A (PKAc), dopamine- and cAMP-
regulated phosphoprotein with 32 kDa molecular weight (DARPP-32). Different phosphorylation states of DARPP-32 are indicated by the
corresponding amino acid(s) and location(s). For instance, (Thr
34-Ser
102) refers to DARPP-32 phosphorylated simultaneously at positions 34 and
102.
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~28.7%, and ~48.9%, respectively. Meanwhile, active
PKA and PP1 show levels of ~0.7 nM and ~4.7 μM,
respectively.
In laboratory experiments, the Thr34 phosphorylation
level rose over 6-fold within 2 to 10 minutes when the
dopamine signal was activated following a stimulus
[17-19], while Thr75 decreased to about half its base
value [16]. Quite consistently, the model shows that
Thr34 increases about 7-fold within 3 minutes and
Thr75 decreases by ~35% following a 5-minute stimula-
tion of 10 μM dopamine. In experiments where dopa-
mine was depleted from the striatum, Thr75 (but not
Thr34) rose substantially [20], and again this observa-
tion is reproduced well in a model simulation.
Similarly, the effects of stimulatory glutamate signals
were assessed. Experiments indicated that an enhanced
or prolonged glutamate signal increases the Ca
2+ con-
centration, which in turn leads to a rapid 50% reduction
in the levels of Thr34 and Thr75 [21,22]. In the corre-
sponding model simulation of a 5-minute stimulation
with 1 μMC a
2+, Thr34 and Thr75 phosphorylation is
reduced to ~30% and ~55% of untreated levels within 1
minute. When the stimulus ceases, it takes about 6 min-
utes for Thr75 and 20 minutes for Thr34 to return to
their basal levels [21,22], and again these simulation
results are consistent with experimental observations.
The dopamine and glutamate signals modulate each
other’s effects on DARPP-32. Using concurrent signals,
the model shows that glutamate inhibits a Thr34
increase and enhances a Thr75 decrease induced by the
dopamine signal, whereas dopamine counteracts a
Thr34 decrease caused by glutamate and raises its level.
Again, these simulation results are consistent with
experimental findings [17].
Genetic and pharmacological interventions to the
DARPP-32 system were also simulated with the model
and the results were compared with experimental data.
The effect of an intervention is simulated most readily
by adjusting the numerical configuration of the model
correspondingly. For example, 90% inhibition of PP2B
by cyclosporin A is implemented as a 90% reduction in
PP2B enzyme activity since the cyclosporin A is not in
the model. Experiments showed that CDK5 inhibition
by 10 μM roscovitine reduced Thr75 by ~73% and
raised Thr34 about 10 fold [16,19,23,24]. Consistently, a
model simulation of CDK5 inhibition showed that
Thr75 decreases by ~60%, while Thr34 increases more
than 7 fold.
Other experiments showed that CDK5 activation by
up-regulation of its activator p35 attenuates the effects
of cocaine-mediated dopamine transmission on raising
Thr34 and reducing Thr75 [25]. This observation is also
well reproduced by a model simulation. Furthermore,
manipulations on some other important kinases and
phosphatases are consistent with experimental observa-
tions. For instance, the model shows that 90% inhibition
of PP2B by cyclosporin A eliminates the effect of Ca
2+
on Thr34 phosphorylation [17], and that almost com-
plete inhibition of PP2A by 1 μM okadaic acid raises the
Thr75 level by over 3 fold [19,22,26].
Effects of different signals
After the model has been tested and proved to have the
ability to reproduce diverse experimental observations, it
can be utilized to study the characteristics and capabil-
ities of the DARPP-32 system in integrating and inter-
preting different types of neuronal signals, as described
in the Methods Section. The main goal of this analysis
was to answer the question of how the DARPP-32 sys-
tem manages to map different input scenarios reliably
into distinct responses. In this section, we analyze the
effects of different inputs on the state of the DARPP-32
system, while the following section will shed light on
the internal mechanisms that implement this mapping.
These modeling activities generate actual predictions
since corresponding experiments have not yet been
documented in the literature.
Relevant signals included dopamine and glutamate sti-
mulation, and they were implemented by specifically
resetting the extracellular dopamine level and the intra-
cellular concentration of Ca
2+, respectively. As discussed
in detail in the Methods Section, we tested different
input signal types, namely: individual or combined dopa-
mine and glutamate signals; transient or sustained sig-
nals; one-shot pulse or repetitive pulse signals; signals of
varying time scale; and signals of high or low amplitude.
To configure these input signals quantitatively, we first
assessed which time scales were most realistic. Accord-
ing to experimental measurements, the dopamine
release stimulated by action potentials at different fre-
quencies can have a time scale of between milliseconds
(< 2 Hz stimuli) and seconds (~20 Hz stimuli) [27]. The
Ca
2+ current responds to a glutamate signal as fast as
milliseconds [28]. Accordingly, we set time scales of
dopamine and calcium signals between milliseconds and
seconds. In accordance with the frequencies of different
brain waves, we set the input signals such that a sus-
tained input has a 5-fold larger width than a transient
input, and that a repetitive input comprises five pulses
instead of one pulse in a one-shot input (Figure 3).
Dopamine signals
When the DARPP-32 system was stimulated with differ-
ent patterns of dopamine signals, its responses were
typically characterized by a spike in PKA and D34 *
(DARPP-32 phosphorylated at Thr34), as well as a
trough in PP1 and D75 * (DARPP-32 phosphorylated at
Thr75) (Figure 4A). The amplitudes of these spikes and
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signal.
Glutamate signals
Glutamate signals are represented in the model as
changes in Ca
2+ i n f l u x .I nr e s p o n s et om o s tt y p e so f
Ca
2+ influx, the DARPP-32 system commonly responded
with spikes in both PKA and PP1, which were accompa-
nied by troughs in D34 *a n dD 75 * (Figure 4B). Com-
pared to responses to dopamine signals, PKA exhibited
an extra undershoot and consequently went through a
refractory period, while D75 * showed an extra overshoot
and a subsequent refractory period. The main distinctive
feature between the effects of dopamine and those of
glutamate is the qualitative difference in the dynamics
of PP1 and D34 *.
Combined signals
When the system was exposed to simultaneous dopa-
mine and glutamate signals, the DARPP-32 system
responses often resembled the responses to Ca
2+ signals
alone (Figure 4C). However, the undershoot in PKA and
its refractory period were no longer seen, and the over-
shoot in D75 * was less obvious or disappeared. The
amplitude of the spike in PKA was determined mainly
by the dopamine, while the amplitude of the trough in
D75 * was mostly attributed to the Ca
2+ flux.
Types of signals
Instead of inducing typical responses as described above,
some signal patterns qualitatively altered the steady state
of the DARPP-32 system or caused unusual dynamic
behaviors. To code the characteristics of a signal pattern
in a succinct notation, we use in the following the nota-
tion [signal time scale (milliseconds or seconds)/signal
number (one-shot or repetitive)/signal shape (transient
or sustained)/signal amplitude (high or low amplitude)].
Transient vs. sustained
At r a n s i e n tC a
2+ signal [milliseconds/repetitive/transi-
ent/high amplitude] had the capability of switching the
DARPP-32 system to a new steady state, which was
characterized by elevated PP1 and reduced levels of
PKA, D34 *, and D75 *. This switch should be seen in
contrast to the complete recovery of the steady state
when the corresponding sustained input signal was
applied (Figure 5).
One-shot vs. repetitive
A one-shot pulse can induce distinctly different
responses of the DARPP-32 system than the corre-
sponding repetitive signal. Figure 6 shows such an
example in the case of a combined signal of dopamine
and Ca
2+: A single pulse (dopamine combined with
Ca
2+, seconds/one-shot/sustained/low amplitude) caused
a trough in PP1, which is in stark contrast to a spike if
the input was a repetitive signal. Also, the one-shot sig-
nal induced a spike in D34 *, while the repetitive pulse
caused a trough. In addition, the spike in D75 *w a s
almost erased in the one-shot scenario.
High vs. low amplitude
A change in signal amplitude can qualitatively alter the
dynamic responses of the DARPP-32 system, as it is
Figure 3 Schematic representation of input signal patterns. The left panel illustrates one-shot scenarios of input signals, while the right
panel shows repetitive input signals. Solid lines represent transient signals, while dashed lines show sustained input signals.
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2+ signal with high amplitude
(seconds/repetitive/sustained/high amplitude) induced a
spike and a refractory period in PKA, while the corre-
sponding signal of low amplitude had almost no effect
on PKA. The high amplitude signal caused a trough in
D75 *, while the low amplitude signal had the opposite
effect. An input signal of high amplitude could also have
a different effect on the steady state of the DARPP-32
system than the corresponding signal of low amplitude.
Figure 8 shows that a combined signal of dopamine and
Ca
2+ (milliseconds/repetitive/transient/high amplitude)
alters the steady state of the DARPP-32 system while
the counterpart signal of low amplitude does not. The
new steady state shown in the high amplitude scenario
has an elevated level of PP1 and reduced level of PKA,
D34 *, and D75 *. The time scale is also important; how-
ever, its effects could be represented by variations in
amplitude and the number of pulses of a signal.
Summarizing this section we can state that different
patterns of input signals are clearly differentiated by the
DARPP-32 signal transduction system and that they are
reflected in the response state of the system (cf.T a b l e
1). The next section investigates the robustness of the
stimulus-response pattern implementation against per-
turbations of its internal mechanisms.
Robustness of signal-response implementation in the
DARPP-32 system
The qualitative differences seen in the static or
dynamic behaviors of the DARPP-32 system in
response to different signal patterns raise an interest-
ing question, namely: What are the governing mechan-
isms responsible for these input-output differences and
how robust are they? It is clear that the distinct system
responses are critical for the proper functioning of the
DARPP-32 signaling network, and that a better eluci-
dation of their mechanistic implementation and
robustness could possibly help deepen our understand-
ing of its functioning, identify weak points in the sys-
tem that are associated with disease outcomes, and
provide targets for therapeutic interventions. Thus, in
this section we employ systematic perturbations to
analyze mechanisms that connect specific signals with
the corresponding responses.
In order to assess the robustness of DARPP-32
mediated signal transduction, we simulated perturba-
tions of all processes within the DARPP-32 system one
by one to discover the most critical processes. We
Figure 4 Typical responses of the DARPP-32 system to
dopamine and glutamate (Ca
2+ influx) signals. Panel A shows a
typical response of the system to a sole dopamine signal, while
panel B exhibits a representative response of the system to a sole
glutamate (Ca
2+ influx) signal. Panel C shows a common response
of the system to a combination of dopamine and Ca
2+ signals.
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and 8 as signal scenarios and in the following describe
their implementation under the categories signal shape
scenario, signal number scenario, signal amplitude sce-
nario - dynamics,a n dsignal amplitude scenario -
steady state. For each scenario, each process within the
DARPP-32 system was separately accelerated or decel-
erated (including complete blockage) to simulate
effects of chemical or genetic perturbations. The effect
of each perturbation was assessed, thereby revealing
the dominant processes of the signal-response imple-
mentation in each scenario.
Signal shape scenario (transient vs. sustained)
The most important result of this line of simulations
affirms the extraordinary robustness of the DARPP-32
system. We systematically altered every process within
the system within a range of 10-fold acceleration or
deceleration and found that no single process was so
critical that such an alteration in its flux would elimi-
nate the system’s ability to discern between a transient
and a sustained Ca
2+ signal; the appropriate steady
states of PKA and PP1 were achieved in all cases. Even
under complete inhibition of a process, the DARPP-32
system usually achieved a different steady state when it
was subjected to different Ca
2+ signals.
However, there are crucial processes that can destroy
the proper response pattern when sufficiently inhibited.
Not surprisingly, processes transducing the Ca
2+ signal
are very important. Especially, blockade of activation of
PP2B by the Ca
2+ signal can eliminate the differences in
steady states and thereby prevent the system from dis-
tinguishing these signals and responding appropriately.
Although these inputs are associated with Ca
2+ signals,
which correspond to glutamatergic stimulation, the
dopamine signal can have a crucial function in this con-
text. Specifically, inhibition of processes for cAMP and
PKA production can equalize responses induced by
transient and sustained Ca
2+ signals and thereby com-
promise signal discernibility. Because of the important
roles of the dopamine pathway and PKA, the inhibition
Figure 5 Different responses of the DARPP-32 system to a transient or a sustained signal. Input signals are repetitive, high-amplitude
Ca
2+ influxes (corresponding to glutamate stimulation) with a time scale of milliseconds. Blue lines: Responses to a transient signal; red lines:
Responses to a sustained signal.
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stantially to variations in the steady state of the DARPP-
32 system.
Signal number scenario (one-shot vs. repetitive signal)
Simulations screening for critical processes in this cate-
gory suggest that the dopamine pathway is crucial for
dynamic differences, especially the production processes
of cAMP and PKA. Phosphodiesterases, which inhibit
the formation of cAMP, similarly make an important
contribution to these differences. The Ca
2+ pathway,
and specifically its activation of PP2B, is also critical for
discerning a one-shot from a repetitive signal.
Signal amplitude scenario (high vs. low amplitude)
Finally, the critical processes for mediating different sig-
nal amplitudes and transducing them to distinct
dynamic transients and steady states of the DARPP-32
system were investigated. The dopamine pathway and
Ca
2+ were both found to be significant contributors.
However, the activation of PP2B was no longer identi-
fied as crucial. Instead, Ca
2+ activation of the
phosphatase PP2A and the interaction between PKA
and PP2A are dominant for both dynamic and static
responses to different signal amplitudes. Although phos-
phodiesterases can inhibit the formation of cAMP and
t h u sr e d u c et h ea c t i v i t yo fP K A ,t h e yc o n t r i b u t eo n l y
negligibly to the observed differences in response to
high and low signal amplitudes.
Discussion
The DARPP-32 system integrates different types of
dopamine and glutamate signals and transduces them
toward appropriate biochemical, cellular, physiological,
and behavioral responses, such as motor behavior [29].
It mediates these crucial functions of neurotransmitters
through regulating the phosphorylation profiles of PKA
and PP1 in an appropriate and adaptive fashion [3,30].
For instance, by means of phosphorylation or depho-
sphorylation of the glutamate receptors, an incoming
neuronal signal can induce changes in the conductance
and/or density of these receptors, thereby changing the
Figure 6 Different responses of the DARPP-32 system to a one-shot or a repetitive signal. Input signals are combinations of a dopamine
signal and Ca
2+ influx. They have low amplitude and a sustained shape with a time scale of seconds. Blue lines: Responses to a one-shot signal;
red lines: Responses to a repetitive signal.
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Ca
2+ channels and neuronal Na
+,K
+-ATPase can be
regulated by neurotransmitters via the DARPP-32 sys-
tem [5]. Furthermore, experiments of DARPP-32 knock-
out mice demonstrated that DARPP-32 contributes to
synaptic plasticity such as long-term depression and
long-term potentiation [34]. These long-term forms of
synaptic plasticity can be induced by altering gene tran-
scription for synaptic function through PKA and PP1
regulation of transcription factors such as CREB and of
immediate early genes such as C-fos and ΔfosB
[5,35-37]. In addition, locomotor activity and reward
behavior can be regulated through the DARPP-32
system.
Thus, a vast array of studies has confirmed that the
DARPP-32 system is a critical mediator for complex
neuronal signal transduction. Combining this documen-
ted function with our detailed model analyses showing
how various patterns of neurotransmission have distinct
effects on the internal state of the DARPP-32 system
raises an important question, namely: Are the different
biochemical states and transient responses of DARPP-32
physiologically and behaviorally significant and could
they even correspond to different phenotypes associated
with striatal function and dysfunction? Complete
answers cannot yet be given and will require further
exploration and discovery through cell and animal
experiments. A biological phenomenon of relevance in
this category is reinforcement learning, with which med-
ium spiny neurons in the striatum can fire more easily
under sole cortical input. This functionality is achieved
through phosphorylation of AMPA receptors, which can
be phosphorylated and dephosphorylated at Ser845 of
its GluR1 subunit by PKA and PP1, respectively. This
type of phosphorylation and dephosphorylation activity
corresponds to the insertion and removal of membrane
associated AMPA receptors, respectively [38,39]. Since
our model suggests that different input signals can lead
to distinct PKA and PP1 activity profiles, it might be
Figure 7 Different dynamics of the DARPP-32 system in response to a high- or a low- amplitude signal. Input signals are repetitive,
sustained Ca
2+ influxes with a time scale of seconds. Blue lines: Responses to a high amplitude signal; red lines: Responses to a low amplitude
signal.
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signals with reinforcement learning.
Systematic simulations of local perturbations affecting
the DARPP-32 system demonstrated that the system is
very robust in its interpretation of the relevant spectrum
of neuronal signals. Even under conditions of 10-fold
acceleration or deceleration of any single process, the
DARPP-32 system was still able to translate input sig-
nals into their correct responses. However, the system
also contains critical components whose perturbation
could interrupt normal behaviors. Among these are
mechanisms transducing the Ca
2+ signal, especially the
activation of PP2B. If this activation is impeded, the
dynamics and/or static states of the system may no
longer reflect the correct input signal.
The model demonstrates in what manner the dopa-
mine pathway plays an indispensable role in signal inter-
pretation. The primary mechanism is the regulation of
the kinase PKA through the production of cAMP and
the phosphorylation level of DARPP-32 at the Thr75
site. Depending on input signal patterns, dopamine and
glutamate can have synergistic or antagonistic interac-
tions, which contribute to distinctly different responses.
The work presented here focuses primarily on the
neurotransmitters dopamine and glutamate. For medium
spiny neurons which receive innervation from excitatory
glutamatergic neurons and modulatory dopaminergic
neurons, our results showed that these two neurotrans-
mitters interact differently within the DARPP-32 system
in response to various input signal patterns. Meanwhile,
different transmitter systems contribute most to
observed discerning capability of different signal pat-
terns. Thus, if an intervention is designed to manipulate
signal discernibility by the DARPP-32 system, the choice
of the targeted neurotransmitter system has to be based
on the specific goal. For such a task, our model can be
used to screen the target and simulate the effects of the
intentional intervention.
It is known that medium spiny neurons also receive
inputs from other neurotransmitters such as serotonin,
Figure 8 Different steady states of the DARPP-32 system in response to a high- or a low- amplitude signal.I n p u ts i g n a l sa r e
combinations of dopamine stimulation and Ca
2+ influx. They are repetitive, transient with a time scale of milliseconds. Blue lines: Responses to a
high amplitude signal; red lines: Responses to a low amplitude signal.
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contribute significantly to functions of medium spiny
neurons. These contributions will be the subject of
future research. It might also be useful to expand the
signal patterns proposed here. For instance, long-term
behaviors lasting minutes, hours, or even longer are
clearly biologically significant and should be studied
with the proposed model as well. Finally, all neuro-
transmitter signals are controlled by action potentials,
ion fluxes, and metabolic pathways in presynapses,
where the neurotransmitters are synthesized, degraded,
compartmentalized, released, and taken back into a
synaptic terminal [40]. Thus, presynapse and postsy-
napse models should be linked in order to account for
a more comprehensive understanding of normal func-
tion and dysfunction of the striatum.
Conclusions
In this study, we investigated systematically and quan-
titatively the capability of a signal transduction system
(the DARPP-32 system) in neuronal signals integration
and interpretation with methods of computational sys-
tems biology. As shown by our results, the DARPP-32
system implements a sophisticated many-to-many
mapping that senses various signal characteristics and
their combinations in terms of their biochemical
source, shape, amplitude, repetition, and time scale
and converts these into distinct internal states. These
states correspond initially to distinct phosphorylation
profiles of the DARPP-32 molecule and are subse-
quently translated into different dynamic and static
activity configurations of the kinase PKA and the
phosphatase PP1.
The amplitude of a signal is a direct function of the
intensity of neurotransmitter release and contributes to
synaptic plasticity. According to our results, different
dopamine and glutamate signal amplitudes can cause
the DARPP-32 to switch among its different steady
states and/or to change its dynamic responses qualita-
tively. Similarly, neurotransmissions of different shapes
and repetition characteristics can be translated through
DARPP-32 into different steady states and/or distinct
dynamic responses. Such dicernibility might have impor-
tant implications in physiological and behavioral phe-
nomena, such as synaptic plasticity.
The discernibility of the DARPP-32 system between
various neurotransmission patterns is associated by our
systemic analyses with mechanisms transducing the
Ca
2+ signal, especially the activation of PP2B, and
mechanisms regulating the kinase PKA through the pro-
duction of cAMP and the phosphorylation level of
DARPP-32 at the Thr75 site.
These mechanisms potentially underlying the dis-
cernibility of the DARPP-32 system need to be verified
experimentally. If the experiments confirm our predic-
tions, these dominant processes have implications for
the vulnerability of the system and for possible thera-
peutic interventions in Parkinson’s disease, schizophre-
nia, and drug addiction. For example, the DARPP-32
system is involved in the generation of dyskinesia, a
severe disorder often associated with Parkinson’sd i s -
ease [41]. It will be of great potential impact to test
whether interventions targeting these critical mechan-
isms in the DARPP-32 system can ameliorate this dis-
order. Efforts are currently in progress to develop
drugs acting on medium spiny neurons [42-44], and it
Table 1 Mapping capability of the DARPP-32 system
between neuronal signals and phosphorylation profiles
of PKA and PP1
Input Signal DARPP-32
Status
Output
Dopamine
a Glutamate
a Thr34
b Thr75
b75 PKA
b PP1
b
Any signal of
millisecond to second
scale
Δ≡ ∇≡ Δ≡ ∇≡
ms-sp-tt-ha ∇↓ ∇↓ ∇↓ Δ↑
ms-sp-tt-la ∇≡ ∇≡ Δ≡ Δ≡
ms-sp-st-ha ∇≡ ∇≡ Δ≡ Δ≡
ms-sp-st-la ∇≡ ∇≡ ↔≡ Δ≡
ms-rp-tt-ha ∇↓ ∇↓ ∇↓ Δ↑
ms-rp-tt-la ∇≡ ∇≡ Δ≡ Δ≡
ms-rp-st-ha/la ∇≡ ∇≡ Δ≡ Δ≡
s-sp-tt-ha ∇≡ ∇≡ Δ≡ Δ≡
s-sp-tt-la ∇≡ ∇≡ ↔≡ ↔≡
s-sp-st-ha ∇≡ ∇≡ Δ≡ Δ≡
s-sp-st-la ∇≡ ↔≡ ↔≡ Δ≡
s-rp-tt-ha/la ∇≡ ∇≡ Δ≡ Δ≡
s-rp-st-ha ∇≡ ∇≡ Δ≡ Δ≡
s-rp-st-la ∇≡ Δ≡ ↔≡ Δ≡
ms-sp-tt-ha ms-sp-tt-ha ∇↓ ∇↓ ∇↓ Δ↑
ms-sp-tt-la ms-sp-tt-la ∇≡ ∇≡ Δ≡ Δ≡
ms-sp-st-ha/la ms-sp-st-ha/la ∇≡ ∇≡ Δ≡ Δ≡
ms-rp-tt-ha ms-rp-tt-ha ∇↓ ∇↓ ∇↓ Δ↑
ms-rp-tt-la ms-rp-tt-la ∇≡ ∇≡ Δ≡ Δ≡
ms-rp-st-ha/la ms-rp-st-ha/la ∇≡ ∇≡ Δ≡ Δ≡
s-sp-tt-ha s-sp-tt-ha ∇≡ ∇≡ Δ≡ Δ≡
s-sp-tt-la s-sp-tt-la Δ≡ ∇≡ Δ≡ ∇≡
s-sp-st-ha/la s-sp-st-ha/la Δ≡ ∇≡ Δ≡ ∇≡
s-rp-tt-ha/la s-rp-tt-ha/la ∇≡ ∇≡ Δ≡ Δ≡
s-rp-st-ha/la s-rp-st-ha/la ∇≡ ∇≡ Δ≡ Δ≡
a: Abbreviations for neurotransmission patterns are: millisecond (ms), second
(s), a single pulse (sp), repetitive pulses (rp), transient transmission (tt),
sustained transmission (st), high amplitude signal (ha), and low amplitude
signal (la).
b: The responses of the DARPP-32 state and its output are presented as
transient dynamics and long-term state. The transient dynamics is described as
trough (∇), essentially flat (↔,a n dpeak (Δ) reflecting the main characteristic of
the response. The long-term state of phosphorylation is given in relation to
the resting level as decreased (↓), basal (≡), and increased (↑).
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Page 11 of 16appears that our model and simulation results could
facilitate a deeper and more detailed understanding of
the specific effects of these drugs. By simulating the
drug mechanism, such model analyses could investi-
gate not only the effects on the anticipated target but
also on all other processes that are affected within the
DARPP-32 system. In addition, one could study with
relative ease how such effects of the drug vary in dif-
ferent context of neuronal signals. Upon further testing
and refinements, which will require additional data and
information, the model will have the potential of asses-
sing the effects of drug interventions on targets and
processes located downstream of the DARPP-32
system.
Methods
The DARPP-32 system includes various types of inter-
actions, such as ligand-receptor binding, enzymatic
reactions, activation, and inhibition. Our model, which
accounts for all these components, is based on models
developed by Lindskog and collaborators, the LeNo-
vère’s lab, and the Greengard’s group [45-47], who stu-
died various static and dynamic behaviors of the
DARPP-32 system, but combines and extends these in
a significant fashion. Its connectivity diagram is shown
in Figures 1 and 2, and all mass action reactions are
listed in Tables 2 and 3. A full, explicit and directly
downloadable description of the model is available in
Additional file 1.
Table 2 Reactions and rate constants of signal transduction for DARPP-32 phosphorylation in dendrites of medium
spiny neurons in the striatum (see legend of Figure 1 for abbreviations)
Reaction Kf(nM
-1. s
-1)
# Kb (s
-1)K c (s
-1) Ref.
D1 + DA ↔ D1_DA 1.1E-3 10.0 [47]
D1_DA + Gabg ↔ D1_DA_Gabg 6.0E-4 1.0E-3 [47]
D1 + Gabg ↔ D1_Gabg 6.0E-5 3.0E-4 [47]
D1_Gabg+D A↔ D1_DA_Gabg 3.3E-3 10.0 [47]
D1_DA_Gabg ® D1_DA + GaGTP+ Gbg 20.0
a [47]
GaGTP ® GaGDP 10.0
a [47]
GaGDP + Gbg ® Gabg 100.0 [47]
GaGTP + AC5 ↔ GaGTP_AC5 3.9E-2 50.0 [47]
GaGTP_AC5 + ATP ↔ GaGTP_AC5_ATP 1.3E-4 2.6E-1 [47]
GaGTP_AC5_ATP ↔ GaGTP_AC5 + cAMP 28.5
a 2.6E-4
b [47]
PKA + 2 cAMP ↔ PKA_cAMP2 1.3E-5
c 6.0E-3 [47]
PKA_cAMP2 + 2 cAMP ↔ PKA_cAMP4 1.7E-5
c 6.0E-2 [47]
PKA_cAMP4 ↔ 2 PKAc + PKAr 5.1E-4
a 4.8E-3
c [47]
PDE1 + cAMP ↔ PDE1_cAMP ® PDE1 + AMP 2.0E-2 72.0 18.0 [47]
PDE4 + cAMP ↔ PDE4_cAMP ® PDE4 + AMP 2.0E-2 72.0 18.0 [47]
PKAc + PDE1 ↔ PKAc_PDE1 ® PKAc + PDE1p 6.0E-3 36.0 9.0 [48]
PDE1p ® PDE1 1.0E-1
a [48]
PKAc + PDE4 ↔ PKAc_PDE4 ® PKAc + PDE4p 6.0E-3 36.0 9.0 [48]
PDE4p ® PDE4 1.0E-1
a [48]
® Ca
2+ 2.5E+1
e [48]
Ca
2+® 0.6
a/1.7
a [48]
2C a
2+ + PP2Bi ↔ PP2Bi_Ca2 1.0E-3
c 1.0 [48]
2C a
2+ + PP2Bi_Ca2 ↔ PP2B 3.0E-3
c 1.0 [48]
AC5 + Ca
2+ ↔ AC5_Ca 1.0E-3 0.9 [47]
GaGTP + AC5_Ca ↔ GaGTP_AC5_Ca 1.9E-2 25.0 [47]
GaGTP_AC5_Ca + ATP ↔ GaGTP_AC5_Ca_ATP 6.0E-5 1.3E-1 [47]
GaGTP_AC5_Ca_ATP ↔ GaGTP_AC5_Ca + cAMP 14.2
a 1.3E-4
b [47]
PP2A + 4 Ca
2+ ↔ PP2Ac 7.7E-12
d 1.0E-2 [47]
PP2A + PKAc ↔ PP2A_PKAc ® PP2Ap + PKAc 2.5E-3 0.3 0.1 [49]
PP2Ap ® PP2A 4.0E-3
a [47]
CK1 ® CK1p 1.0
a [47]
PP2B + CK1p ↔ PP2B_CK1p ® PP2B + CK1 3.0E-2 24.0 6.0 [47]
CDK5 + Ca
2+ ↔ CDK5c 3.0E-3 1.0
a: Unit in s
-1;
b: Unit in nM
-1·s
-1;
c: Unit in nM
-2·s
-1;
d: Unit in nM
-4·s
-1;
e: Unit in nM·s
-1
#: For a chemical reaction, Kf is the rate constant for the forward process, Kb is the rate constant for the backward process, while Kc is the rate constant for the
catalytic step in a Michaelis-Menten kinetics.
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Page 12 of 16Table 3 Reactions and rate constants of DARPP-32 phosphorylation in dendrites of medium spiny neurons in the
striatum (see legend of Figure 1 for abbreviations)
Reaction Kf(nM
-1·s
-1)
# Kb (s
-1)K c (s
-1) Ref.
D + PKAc ↔ D_PKAc ® D34 + PKAc 5.6E-3 10.8 2.7 [16,50]
D34 + PP2B ↔ D34_PP2B ® D + PP2B 1.0E-3 2.0 0.5 [19]
D + CDK5 ↔ D_CDK5 ® D75 + CDK5 4.5E-4 2.0 0.5 [47]
D75 + PP2Ap ↔ D75_PP2Ap ® D + PP2Ap 4.0E-4 12.0 3.0 [47]
D75 + PP2A ↔ D75_PP2A ® D + PP2A 1.0E-4 6.4 1.6 [47]
D75 + PP2Ac ↔ D75_PP2Ac ® D + PP2Ac 4.0E-4 12.0 3.0 [47]
D + CK2 ↔ D_CK2 ® D102 + CK2 4.0E-4 6.4 1.6 [51]
D102 ® D 1.6
a
D + CK1 ↔ D_CK1 ® D137 + CK1 4.4E-3 12.0 3.0 [25]
D137 + PP2C ↔ D137_PP2C ® D + PP2C 7.5E-3 12.0 3.0 [47]
D102 + PKAc ↔ D102_PKAc ® D34:102 + PKAc 5.6E-3 10.8 2.7
D34:102 + PP2B ↔ D34:102_PP2B ® D102 + PP2B 7.5E-5 0.12 0.03
D137 + PKAc ↔ D137_PKAc ® D34:137 + PKAc 5.6E-3 10.8 2.7 [16,50]
D34:137 + PP2B ↔ D34:137_PP2B ® D137 + PP2B 7.5E-5 0.12 0.03 [25]
D102 + CDK5 ↔ D102_CDK5 ® D75:102 + CDK5 4.5E-4 2.0 0.5
D75:102 + PP2Ap ↔ D75:102_PP2Ap ® D102 + PP2Ap 4.0E-4 12.0 3.0
D75:102 + PP2A ↔ D75:102_PP2A ® D102 + PP2A 1.0E-4 6.4 1.6
D75:102 + PP2Ac ↔ D75:102_PP2Ac ® D102 + PP2Ac 4.0E-4 12.0 3.0
D137 + CDK5 ↔ D137_CDK5 ® D75:137 + CDK5 4.5E-4 2.0 0.5
D75:137 + PP2Ap ↔ D75:137_PP2Ap ® D137 + PP2Ap 4.0E-4 12.0 3.0
D75:137 + PP2A ↔ D75:137_PP2A ® D137 + PP2A 1.0E-4 6.4 1.6
D75:137 + PP2Ac ↔ D75:137_PP2Ac ® D137 + PP2Ac 4.0E-4 12.0 3.0
D34 + CK2 ↔ D34_CK2 ® D34:102 + CK2 4.0E-4 6.4 1.6
D34:102 ® D34 1.6
a
D75 + CK2 ↔ D75_CK2 ® D75:102 + CK2 4.0E-4 6.4 1.6
D75:102 ® D75 1.6
a
D34 + CK1 ↔ D34_CK1 ® D34:137 + CK1 4.4E-3 12.0 3.0 [25]
D34:137 + PP2C ↔ D34:137_PP2C ® D34 + PP2C 7.5E-3 12.0 3.0 [47]
D75 + CK1 ↔ D75_CK1 ® D75:137 + CK1 4.4E-3 12.0 3.0 [25]
D75:137 + PP2C ↔ D75:137_PP2C ® D75 + PP2C 7.5E-3 12.0 3.0 [47]
D102 + CK1 ↔ D102_CK1 ® D102:137 + CK1 4.4E-3 12.0 3.0
D102:137 + PP2C ↔ D102:137_PP2C ® D102 + PP2C 7.5E-3 12.0 3.0
D137 + CK2 ↔ D137_CK2 ® D102:137 + CK2 4.0E-4 6.4 1.6
D102:137 ® D137 1.6
a
D34:102 + CK1 ↔ D34:102_CK1 ® D34:102:137 + CK1 4.4E-3 12.0 3.0
D34:102:137 + PP2C ↔ D34:102:137_PP2C ® D34:102 + PP2C 7.5E-3 12.0 3.0
D34:137 + CK2 ↔ D34:137_CK2 ® D34:102:137 + CK2 4.0E-4 6.4 1.6
D34:102:137 ® D34:137 1.6
a
D102:137 + PKAc ↔ D102:137_PKAc ® D34:102:137 + PKAc 5.6E-3 10.8 2.7
D34:102:137 + PP2B ↔ D34:102:137_PP2B ® D102:137 + PP2B 7.5E-5 0.12 0.03
D75:102 + CK1 ↔ D75:102_CK1 ® D75:102:137 + CK1 4.4E-3 12.0 3.0
D75:102:137 + PP2C ↔ D75:102:137_PP2C ® D75:102 + PP2C 7.5E-3 12.0 3.0
D75:137 + CK2 ↔ D75:137_CK2 ® D75:102:137 + CK2 4.0E-4 6.4 1.6
D75:102:137 ® D75:137 1.6
a
D102:137 + CDK5 ↔ D102:137_CDK5 ® D75:102:137 + CDK5 4.5E-4 2.0 0.5
D75:102:137 + PP2Ap ↔ D75:102:137_PP2Ap ® D102:137 + PP2Ap 4.0E-4 12.0 3.0
D75:102:137 + PP2A ↔ D75:102:137_PP2A ® D102:137 + PP2A 1.0E-4 6.4 1.6
D75:102:137 + PP2Ac ↔ D75:102:137_PP2Ac ® D102:137 + PP2Ac 4.0E-4 12.0 3.0
D34 + PP1 ↔ D34_PP1 0.4 0.6 [47]
D34_PP1 + PP2B ↔ D34_PP1_PP2B ® D + PP1 + PP2B 1.0E-3 2.0 0.5 [47]
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Page 13 of 16Figure 1 indicates that dopamine can bind to its D1
receptors on the postsynaptic membrane, where it
forms a complex with the corresponding G protein.
The complex releases its alpha subunit, which binds to
adenylate cyclase (AC5) and generates cAMP. This
second messenger binds to the regulatory subunit of
PKA and releases its catalytic subunit, which phos-
phorylates DARPP-32 at threonine 34 (Thr34, posi-
tioned according to the rat sequence). Counteracting
this effect, the same site is dephosphorylated by the
phosphatase PP2B. DARPP-32 can also be phosphory-
l a t e da tas e c o n dt h r e o n i n es i t e( T h r 7 5 ,p o s i t i o n e d
according to the rat sequence) by CDK5, a process
which is counteracted by protein phosphatase 2A
(PP2A), which mediates the release of the phosphate
group from this site. DARPP-32 possesses two further
phosphorylation sites, namely serine 102 and serine
137 (Ser102 and Ser137, positioned according to the
rat sequence). Casein kinase 1 (CK1) and casein kinase
2 (CK2) execute the phosphorylation at Ser137 and
Ser102, respectively.
These phosphorylation sites of DARPP-32 can be
phosphorylated simultaneously, and transitions between
different phosphorylation configurations are illustrated
in Figure 2. However, phosphorylation activities at these
sites are not independent of each other. For example,
Ser102 and Ser137 phosphorylation of DARPP-32 can
activate phosphorylation and repress dephosphorylation
of DARPP-32 at Thr34, respectively. Importantly,
DARPP-32 with Thr75 phosphorylation can bind to
PKA and inhibit its capability to phosphorylate DARPP-
32 at Thr34, which permits us to exclude the combined
phosphorylation form of Thr34-Thr75 [16,47]. It is evi-
dent that the signal cascade becomes a complicated net-
work when all possible interactions are taken into
account.
We model this signaling system with ordinary differ-
ential equations for all variables (molecules) in Tables 2
and 3 according to the law of mass action. Each process
is formulated as a product of concentrations of contri-
butors raised to the relevant reaction orders (most of
which are 1), and multiplied with the appropriate rate
constant. An enzymatic reaction is assumed to follow a
reversible Michaelis-Menten mechanism with forward,
backward, and catalytic steps that are quantified by the
rate constants Kf, Kb,a n dKc, respectively. A non-enzy-
matic reaction is treated with both forward and back-
ward steps or as a single irreversible forward step
reaction. The derivative of each variable is determined
b yt h ed i f f e r e n c eb e t w e e nt h es u mo fi t si n f l u x e sa n d
the sum of its effluxes; the equations are explicitly given
in Additional file 1. The dynamics of the signaling net-
work is obtained as the solution of the system of
equations.
Table 3: Reactions and rate constants of DARPP-32 phosphorylation in dendrites of medium spiny neurons in the
striatum (see legend of Figure 1 for abbreviations) (Continued)
D34:102 + PP1 ↔ D34:102_PP1 0.4 0.6
D34:102_PP1 + PP2B ↔ D34:102_PP1_PP2B ® D102 + PP1 + PP2B 1.0E-3 2.0 0.5
D34:137 + PP1 ↔ D34:137_PP1 0.4 0.6
D34:137_PP1 + PP2B ↔ D34:137_PP1_PP2B ® D137 + PP1 + PP2B 1.0E-3 2.0 0.5
D34:102:137 + PP1 ↔ D34:102:137_PP1 0.4 0.6
D34:102:137_PP1 + PP2B ↔ D34:102:137_PP1_PP2B ® D102:137 + PP1 + PP2B 1.0E-3 2.0 0.5
D75 + PKAc ↔ D75_PKAc 5.6E-3 10.8 [16]
D75:102 + PKAc ↔ D75:102_PKAc 5.6E-3 10.8
D75:137 + PKAc ↔ D75:137_PKAc 5.6E-3 10.8
D75:102:137 + PKAc ↔ D75:102:137_PKAc 5.6E-3 10.8
a: Unit in s
-1
#: For a chemical reaction, Kf is the rate constant for the forward process, Kb is the rate constant for the backward process, while Kc is the rate constant for the
catalytic step in a Michaelis-Menten kinetics.
Table 4 Initial values for the DARPP-32 phosphorylation
system in dendrites of medium spiny neurons in the
striatum (see legend of Figure 1 for abbreviations)
Molecule Concentration (nM) Reference
DA 10.0 [45]
D1 5.0E+2 [45]
Gabg 3.0E+3 [45]
AC5 2.5E+3 [45]
ATP 2.0E+6 [45]
PDE1 4.0E+3 [45]
PDE4 2.0E+3 [45]
DARPP-32 5.0E+4 [52]
PKA 1.2E+3 [53]
PP2Bi 4.0E+3 [45]
CDK5 1.8E+3 [45]
PP2A 2.0E+3 [54,55]
CK1 2.0E+3
PP2C 2.0E+3
PP1 5.0E+3 [56,57]
CK2 2.0E+3
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Page 14 of 16To gain quantitative insights, values for rate con-
s t a n t s ,r e a c t i o no r d e r s ,a n dinitial variable states are
needed. This information is presented in Tables 2, 3
and 4, which were populated with information from
the literature and databases such as BRENDA http://
www.brenda-enzymes.info/. Some values were com-
puted from kinetic data, while others (mostly rate con-
stants for transitions between different forms of
phosphorylation) were specified with reasonable
estimates.
Once the numerical characterization was completed, it
was straightforward to test different scenarios, for
instance, by exposing the system to various signals and
to random perturbations. Representative input patterns
consist of combinations of the following signal specifica-
tions:
a. individual or combined dopamine and glutamate
signals;
b. transient or sustained signals;
c. one-shot pulse or repetitive pulse signals;
d. signals of varying length;
e. signals of high or low amplitude.
The input signals were simulated in terms of different
combinations of these specifications, and their effects on
signal integration by DARPP-32 without or with pertur-
bations were systematically evaluated.
The responses to the different input signals were
examined from two distinct and relevant viewpoints.
First, long-term effects indicate whether the system can
switch to a different steady state, and if so, how large in
magnitude the change is. Second, the transient effects,
which are obtained as the dynamic behavior, reflect
short-term responses of the system. Critical output vari-
ables for these responses are PKA and PP1. In addition
to these two indicators, the phosphorylation profile of
DARPP-32 can serve as a valuable sentinel, because it
represents the internal state of the signal transduction
system, while PKA and PP1 are functional proteins per-
forming biochemical, cellular, and physiological
regulations.
Additional file 1: The DARPP-32 model. This is a computational model
of the DARPP-32 system in the human striatum using ordinary
differential equations.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1752-0509-4-26-
S1.DOC]
Acknowledgements
This work was supported by a grant from the National Institutes of Health
(P01-ES016731, G.W.M. PI) and an endowment from the Georgia Research
Alliance (E.O.V). Any opinions, findings, and conclusions or recommendations
expressed in this material are those of the authors and do not necessarily
reflect the views of the sponsoring institutions.
Author details
1Department of Biomedical Engineering, Georgia Institute of Technology and
Emory University Medical School, Atlanta, GA 30332, USA.
2Center for
Neurodegenerative Disease, Emory University School of Medicine, Atlanta,
GA 30322, USA.
3Integrative BioSystems Institute, Georgia Institute of
Technology, Atlanta, GA 30332, USA.
4Department of Environmental and
Occupational Health, Rollins School of Public Health, Emory University,
Atlanta, GA 30322, USA.
Authors’ contributions
ZQ carried out the modeling, analyses and interpretation of results, and
manuscript writing. GWM participated in the design of the work and help to
draft the manuscript. EOV conceived the study, interpreted results, and
wrote the manuscript. All authors have read and approved the manuscript.
Received: 3 December 2009 Accepted: 17 March 2010
Published: 17 March 2010
References
1. Graybiel AM: Neurotransmitters and neuromodulators in the basal
ganglia. Trends Neurosci 1990, 13:244-254.
2. Walaas SI, Aswad DW, Greengard P: A dopamine- and cyclic AMP-
regulated phosphoprotein enriched in dopamine-innervated brain
regions. Nature 1983, 301:69-71.
3. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P:
DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol
Toxicol 2004, 44:269-296.
4. Greengard P, Allen PB, Nairn AC: Beyond the dopamine receptor: the
DARPP-32/protein phosphatase-1 cascade. Neuron 1999, 23:435-447.
5. Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A,
Cheramy A, O’Callaghan JP, Miller DB, Cole DG, et al: DARPP-32: regulator
of the efficacy of dopaminergic neurotransmission. Science 1998,
281:838-842.
6. Fienberg AA, Greengard P: The DARPP-32 knockout mouse. Brain Res Brain
Res Rev 2000, 31:313-319.
7. Spencer HJ: Antagonism of cortical excitation of striatal neurons by
glutamic acid diethyl ester: evidence for glutamic acid as an excitatory
transmitter in the rat striatum. Brain Res 1976, 102:91-101.
8. Girault JA, Spampinato U, Savaki HE, Glowinski J, Besson MJ: In vivo release
of [3H]gamma-aminobutyric acid in the rat neostriatum–I.
Characterization and topographical heterogeneity of the effects of
dopaminergic and cholinergic agents. Neuroscience 1986, 19:1101-1108.
9. Nishi A, Kuroiwa M, Miller DB, O’Callaghan JP, Bateup HS, Shuto T,
Sotogaku N, Fukuda T, Heintz N, Greengard P, Snyder GL: Distinct roles of
PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the
striatum. J Neurosci 2008, 28:10460-10471.
10. Hemmings HC Jr, Greengard P, Tung HY, Cohen P: DARPP-32, a
dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of
protein phosphatase-1. Nature 1984, 310:503-505.
11. Kesavapany S, Li BS, Amin N, Zheng YL, Grant P, Pant HC: Neuronal cyclin-
dependent kinase 5: role in nervous system function and its specific
inhibition by the Cdk5 inhibitory peptide. Biochim Biophys Acta 2004,
1697:143-153.
12. Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttila T: Cleavage of the
cyclin-dependent kinase 5 activator p35 to p25 does not induce tau
hyperphosphorylation. Biochem Biophys Res Commun 2002, 298:693-698.
13. Dhavan R, Greer PL, Morabito MA, Orlando LR, Tsai LH: The cyclin-
dependent kinase 5 activators p35 and p39 interact with the alpha-
subunit of Ca2+/calmodulin-dependent protein kinase II and alpha-
actinin-1 in a calcium-dependent manner. J Neurosci 2002, 22:7879-7891.
14. Nishi A, Snyder GL, Greengard P: Bidirectional regulation of DARPP-32
phosphorylation by dopamine. J Neurosci 1997, 17:8147-8155.
15. Jin M, Bateup H, Padovan JC, Greengard P, Nairn AC, Chait BT: Quantitative
analysis of protein phosphorylation in mouse brain by hypothesis-driven
multistage mass spectrometry. Anal Chem 2005, 77:7845-7851.
16. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT,
Girault JA, Czernik AJ, et al: Phosphorylation of DARPP-32 by Cdk5
modulates dopamine signalling in neurons. Nature 1999, 402:669-671.
Qi et al. BMC Systems Biology 2010, 4:26
http://www.biomedcentral.com/1752-0509/4/26
Page 15 of 1617. Snyder GL, Galdi S, Fienberg AA, Allen P, Nairn AC, Greengard P: Regulation
of AMPA receptor dephosphorylation by glutamate receptor agonists.
Neuropharmacology 2003, 45:703-713.
18. Walaas SI, Greengard P: DARPP-32, a dopamine- and adenosine 3’:5’-
monophosphate-regulated phosphoprotein enriched in dopamine-
innervated brain regions. I. Regional and cellular distribution in the rat
brain. J Neurosci 1984, 4:84-98.
19. Nishi A, Bibb JA, Snyder GL, Higashi H, Nairn AC, Greengard P:
Amplification of dopaminergic signaling by a positive feedback loop.
Proc Natl Acad Sci USA 2000, 97:12840-12845.
20. Brown AM, Deutch AY, Colbran RJ: Dopamine depletion alters
phosphorylation of striatal proteins in a model of Parkinsonism. Eur J
Neurosci 2005, 22:247-256.
21. Fischer W, Franke H, Scheibler P, Allgaier C, Illes P: AMPA-induced Ca(2+)
influx in cultured rat cortical nonpyramidal neurones: pharmacological
characterization using fura-2 microfluorimetry. Eur J Pharmacol 2002,
438:53-62.
22. Nishi A, Bibb JA, Matsuyama S, Hamada M, Higashi H, Nairn AC,
Greengard P: Regulation of DARPP-32 dephosphorylation at PKA- and
Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin
and protein phosphatase-2A. J Neurochem 2002, 81:832-841.
23. Chergui K, Svenningsson P, Greengard P: Cyclin-dependent kinase 5
regulates dopaminergic and glutamatergic transmission in the striatum.
Proc Natl Acad Sci USA 2004, 101:2191-2196.
24. Chen PC, Chen JC: Enhanced Cdk5 activity and p35 translocation in the
ventral striatum of acute and chronic methamphetamine-treated rats.
Neuropsychopharmacology 2005, 30:538-549.
25. Takahashi S, Ohshima T, Cho A, Sreenath T, Iadarola MJ, Pant HC, Kim Y,
Nairn AC, Brady RO, Greengard P, Kulkarni AB: Increased activity of cyclin-
dependent kinase 5 leads to attenuation of cocaine-mediated dopamine
signaling. Proc Natl Acad Sci USA 2005, 102:1737-1742.
26. Nishi A, Watanabe Y, Higashi H, Tanaka M, Nairn AC, Greengard P:
Glutamate regulation of DARPP-32 phosphorylation in neostriatal
neurons involves activation of multiple signaling cascades. Proc Natl
Acad Sci USA 2005, 102:1199-1204.
27. Sun JY, Wu XS, Wu LG: Single and multiple vesicle fusion induce different
rates of endocytosis at a central synapse. Nature 2002, 417:555-559.
28. Meinrenken CJ, Borst JG, Sakmann B: Local routes revisited: the space and
time dependence of the Ca2+ signal for phasic transmitter release at
the rat calyx of Held. J Physiol 2003, 547:665-689.
29. Fisone G, Hakansson K, Borgkvist A, Santini E: Signaling in the basal
ganglia: postsynaptic and presynaptic mechanisms. Physiol Behav 2007,
92:8-14.
30. Greengard P: The neurobiology of slow synaptic transmission. Science
2001, 294:1024-1030.
31. Yan Z, Hsieh-Wilson L, Feng J, Tomizawa K, Allen PB, Fienberg AA, Nairn AC,
Greengard P: Protein phosphatase 1 modulation of neostriatal AMPA
channels: regulation by DARPP-32 and spinophilin. Nat Neurosci 1999,
2:13-17.
32. Flores-Hernandez J, Hernandez S, Snyder GL, Yan Z, Fienberg AA, Moss SJ,
Greengard P, Surmeier DJ: D(1) dopamine receptor activation reduces
GABA(A) receptor currents in neostriatal neurons through a PKA/DARPP-
32/PP1 signaling cascade. J Neurophysiol 2000, 83:2996-3004.
33. Flores-Hernandez J, Cepeda C, Hernandez-Echeagaray E, Calvert CR,
Jokel ES, Fienberg AA, Greengard P, Levine MS: Dopamine enhancement
of NMDA currents in dissociated medium-sized striatal neurons: role of
D1 receptors and DARPP-32. J Neurophysiol 2002, 88:3010-3020.
34. Calabresi P, Gubellini P, Centonze D, Picconi B, Bernardi G, Chergui K,
Svenningsson P, Fienberg AA, Greengard P: Dopamine and cAMP-
regulated phosphoprotein 32 kDa controls both striatal long-term
depression and long-term potentiation, opposing forms of synaptic
plasticity. J Neurosci 2000, 20:8443-8451.
35. Hyman SE, Malenka RC: Addiction and the brain: the neurobiology of
compulsion and its persistence. Nat Rev Neurosci 2001, 2:695-703.
36. Liu FC, Graybiel AM: Spatiotemporal dynamics of CREB phosphorylation:
transient versus sustained phosphorylation in the developing striatum.
Neuron 1996, 17:1133-1144.
37. Svenningsson P, Fienberg AA, Allen PB, Moine CL, Lindskog M, Fisone G,
Greengard P, Fredholm BB: Dopamine D(1) receptor-induced gene
transcription is modulated by DARPP-32. J Neurochem 2000, 75:248-257.
38. Lee HK, Barbarosie M, Kameyama K, Bear MF, Huganir RL: Regulation of
distinct AMPA receptor phosphorylation sites during bidirectional
synaptic plasticity. Nature 2000, 405:955-959.
39. Mangiavacchi S, Wolf ME: Stimulation of N-methyl-D-aspartate receptors,
AMPA receptors or metabotropic glutamate receptors leads to rapid
internalization of AMPA receptors in cultured nucleus accumbens
neurons. Eur J Neurosci 2004, 20:649-657.
40. Qi Z, Miller GW, Voit EO: Computational systems analysis of dopamine
metabolism. PLoS ONE 2008, 3:e2444.
41. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G,
Cenci MA, Calabresi P: Loss of bidirectional striatal synaptic plasticity in L-
DOPA-induced dyskinesia. Nat Neurosci 2003, 6:501-506.
42. Langmead CJ, Watson J, Reavill C: Muscarinic acetylcholine receptors as
CNS drug targets. Pharmacol Ther 2008, 117:232-243.
43. Sato K, Ueda H, Okumura F, Misu Y: Supersensitization of intrastriatal
dopamine receptors involved in opposite regulation of acetylcholine
release in Parkinson’s model rats. Neurosci Lett 1994, 173:59-62.
44. Phillips JM, Lam HA, Ackerson LC, Maidment NT: Blockade of mGluR
glutamate receptors in the subthalamic nucleus ameliorates motor
asymmetry in an animal model of Parkinson’s disease. Eur J Neurosci
2006, 23:151-160.
45. Lindskog M, Kim M, Wikstrom MA, Blackwell KT, Kotaleski JH: Transient
calcium and dopamine increase PKA activity and DARPP-32
phosphorylation. PLoS Comput Biol 2006, 2:e119.
46. Barbano PE, Spivak M, Flajolet M, Nairn AC, Greengard P, Greengard L: A
mathematical tool for exploring the dynamics of biological networks.
Proc Natl Acad Sci USA 2007, 104:19169-19174.
47. Fernandez É, Schiappa R, Girault JA, Le Novère N: DARPP-32 is a robust
integrator of dopamine and glutamate signals. PLoS Comput Biol 2006, 2:
e176.
48. Bhalla US, Iyengar R: Emergent properties of networks of biological
signaling pathways. Science 1999, 283:381-387.
49. Usui H, Inoue R, Tanabe O, Nishito Y, Shimizu M, Hayashi H, Kagamiyama H,
Takeda M: Activation of protein phosphatase 2A by cAMP-dependent
protein kinase-catalyzed phosphorylation of the 74-kDa B” (delta)
regulatory subunit in vitro and identification of the phosphorylation
sites. FEBS Lett 1998, 430:312-316.
50. Hemmings HC Jr, Nairn AC, Greengard P: DARPP-32, a dopamine- and
adenosine 3’:5’-monophosphate-regulated neuronal phosphoprotein. II.
Comparison of the kinetics of phosphorylation of DARPP-32 and
phosphatase inhibitor 1. J Biol Chem 1984, 259:14491-14497.
51. Girault JA, Hemmings HC Jr, Williams KR, Nairn AC, Greengard P:
Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated
phosphoprotein, by casein kinase II. J Biol Chem 1989, 264:21748-21759.
52. Hemmings HC Jr, Greengard P: DARPP-32, a dopamine- and adenosine
3’:5’-monophosphate-regulated phosphoprotein: regional, tissue, and
phylogenetic distribution. J Neurosci 1986, 6:1469-1481.
53. Hofmann F, Bechtel PJ, Krebs EG: Concentrations of cyclic AMP-
dependent protein kinase subunits in various tissues. J Biol Chem 1977,
252:1441-1447.
54. Nagase T, Murakami T, Nozaki H, Inoue R, Nishito Y, Tanabe O, Usui H,
Takeda M: Tissue and subcellular distributions, and characterization of
rat brain protein phosphatase 2A containing a 72-kDa delta/B” subunit. J
Biochem 1997, 122:178-187.
55. Sim AT, Ratcliffe E, Mumby MC, Villa-Moruzzi E, Rostas JA: Differential
activities of protein phosphatase types 1 and 2A in cytosolic and
particulate fractions from rat forebrain. J Neurochem 1994, 62:1552-1559.
56. Ouimet CC, da Cruz e Silva EF, Greengard P: The alpha and gamma 1
isoforms of protein phosphatase 1 are highly and specifically
concentrated in dendritic spines. Proc Natl Acad Sci USA 1995,
92:3396-3400.
57. Desdouits F, Cheetham JJ, Huang HB, Kwon YG, da Cruz e Silva EF,
Denefle P, Ehrlich ME, Nairn AC, Greengard P, Girault JA: Mechanism of
inhibition of protein phosphatase 1 by DARPP-32: studies with
recombinant DARPP-32 and synthetic peptides. Biochem Biophys Res
Commun 1995, 206:652-658.
doi:10.1186/1752-0509-4-26
Cite this article as: Qi et al.: The internal state of medium spiny neurons
varies in response to different input signals. BMC Systems Biology 2010
4:26.
Qi et al. BMC Systems Biology 2010, 4:26
http://www.biomedcentral.com/1752-0509/4/26
Page 16 of 16